ARD Podcast | BMJ Group (original) (raw)
Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured. ARD is the official journal of EULAR.
Episodes
Friday Jun 21, 2024
Join our host Dr. Fabian Proft, ARD's Social Media Advisor, as he discusses the updated 2023 EULAR recommendations for imaging in large vessel vasculitis (LVV) with Professor Christian Dejaco and Dr. Milena Bond, the lead authors of the manuscript. This episode covers the latest evidence on ultrasound, MRI, CT, and FDG-PET for diagnosing and monitoring LVV.
Key highlights include:
Ultrasound as the first-line imaging test for giant cell arteritis.
Preferred imaging modalities for Takayasu arteritis.
Use of imaging for assessing vessel abnormalities and long-term monitoring.
Insights into the research agenda for imaging in large vessel vasculitides.
Tune in to learn how these updates aim to enhance patient care and stay informed on the latest developments in rheumatology imaging.Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page - https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059 .
Monday Apr 22, 2024
This podcast brings you the 2023 update on the EULAR recommendations for the management of systemic lupus erythematosus (SLE).
ARD's Social Media Advisor, Professor Laura Andreoli, speaks to Professors Antonios Fanouriakis and Dimitrios Boumpas, both from the "Attikon" University Hospital, National and Kapodistrian University of Athens, Greece, two of the authors of the recommendations paper. Read it on the ARD website: https://ard.bmj.com/content/83/1/15.
Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page - https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059 .
Monday Oct 30, 2023
In this podcast, we discuss the evidence-based EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).ARD's Social Media Advisor, Professor Laura Andreoli, speaks to Professor Carina Boström and Professor Ioannis Parodis, both from the Karolinska Institutet and the Karolinska University Hospital, Stockholm, Sweden, about their recent paper. Read it on the ARD website: https://ard.bmj.com/content/early/2023/08/23/ard-2023-224416
Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Google Podcasts, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page -https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059 .
Monday Feb 07, 2022
In this podcast, Dr. Truchetet discusses her work on the role of innate lymphoid cells in the fibrotic processes in systemic sclerosis (SSc) patients. The group of Dr. Truchetet found that ILC2 are crucial mediators of skin fibrosis in SSc and that combined treatment of patients with TGFb inhibitors and IL-10 might be an attractive new therapeutic approach in SSc.
Read the full paper on the ARD website: https://ard.bmj.com/content/80/12/1594
Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Google Podcasts, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page (https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059).
Thursday Jul 29, 2021
In this podcast, we invite two authors from recent ARD papers dedicated to the efficacy of mRNA vaccines in patients with immunosuppressive therapies.
Christophe Richez, Department of Rheumatology, University Medical Center, Bordeaux, France, and ARD's Social Media Advisor, interviews Bimba Hoyer, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Germany, and Rebecca H Haberman, Division of Rheumatology, University Grossman School of Medicine, New York, USA. They describe their works and offer their thoughts on the current situation in this area and the future.
Related content:
https://ard.bmj.com/content/early/2021/05/11/annrheumdis-2021-220272
https://ard.bmj.com/content/early/2021/06/07/annrheumdis-2021-220597
Thursday Mar 18, 2021
The EULAR COVID-19 database and the COVID-19 Global Rheumatology Alliance work together on shared collected data to address the most pertinent questions in regard to risks for people with rheumatic diseases and COVID-19 infection. The latest study confirms already known risk factors for more severe disease and explores associations between treatments and the risk of death.
In this podcast, ARD’s social media editor, Dr Paul Studenic, is joined by Prof. Pedro Machado, from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, London, UK, to discuss the paper “Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry” (http://dx.doi.org/10.1136/annrheumdis-2020-219498).
Tuesday Sep 15, 2020
Capturing disease progression in SSc is challenging. Becker and colleagues addressed this problem by identifying predictors of disease worsening in the EUSTAR cohort. ARD's social media advisor Dr. Caroline Ospelt talks to Dr. Mike Becker about the results of this analysis.
Read the paper: ard.bmj.com/content/78/9/1242
Thursday Aug 06, 2020
In this podcast, Dr. Paul Studenic speaks to Dr. Sofia Ramiro and Prof. Robert Landewé both engaged in clinical work in the Zuyderland Medical Center in the south of the Netherlands about their clinical study evaluating systemic glucocorticoids and Il-6 blockade as second-line treatment for COVID-19-associated cytokine storm syndrome. They tell the story of the set-up of a peculiar trial using historical patients treated with supportive care as controls to the ‘experimental’ treatment strategy during these unprecedented times of March and April 2020.
Link to article: https://ard.bmj.com/content/79/9/1143
Link to EULAR press release: https://www.eular.org/sysModules/obxContent/files/www.eular.2015/1\_42291DEB-50E5-49AE-5726D0FAAA83A7D4/eular\_glucocorticoids\_and\_il\_6\_receptor\_can\_reduce\_covid19\_css\_related\_hospital\_mortality\_(002).pdf
Wednesday Apr 22, 2020
Statins are some of the most commonly prescribed cholesterol-lowering drugs. They act by inhibiting HMG-CoA reductase, the main enzyme in the synthesis of cholesterol. Earlier studies have shown that statins have an osteoprotective effect: a recently published paper has shown that there is a dose-dependent relationship between different kinds of statins with diagnosis of osteoporosis. "We could find an underrepresentation of osteoporosis in low-dose and an overrepresentation in high-dose statin treatment," says first author Dr. Michael Leutner, MSc PhD (Department of Internal Medicine 3, Division of Endocrinology and Metabolism, Medical University of Vienna), who discusses the details of his study with Dr. Paul Studenic in this podcast.
Read the paper: https://ard.bmj.com/content/78/12/1706
Wednesday Mar 25, 2020
In this podcast recorded at the ACR meeting 2019, Dr. Caroline Ospelt speaks to Prof. Anca Catrina and Dr. Aase Hensvold both of the Division of Rheumatology at the Department of Medicine located at the Karolinska Institute in Stockholm Sweden.
Hensvold et al. developed a prediction score by combining several clinical and blood-based markers that could be useful in predicting which patients with auto-antibodies and musculoskeletal symptoms develop ultrasound-detectable arthritis. These are the first results of an ongoing study on individuals at-risk for rheumatoid arthritis.
The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.